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altered distribution and decreased fibrillin-1 expression in 
the aorta and a significantly lower level of differentiated 
VSMC markers. Interestingly, markers predictive for aor-
tic dilation in BAV were not expressed in the MFS aorta. 
The aorta in MFS was similar to the aorta in dilated TAV 
with regard to the presence of medial degeneration and 
apoptosis, while other markers for degeneration and aging 
like inflammation and progerin expression were low in 
MFS, comparable to BAV. Both MFS and BAV aortas have 
immature VSMCs, while MFS and TAV patients have a 
similar increased rate of medial degeneration. However, the 
mechanism leading to apoptosis is expected to be different, 
being fibrillin-1 mutation induced increased angiotensin-
receptor-pathway signaling in MFS and cardiovascular 
aging and increased progerin in TAV. Our findings could 
explain why angiotensin inhibition is successful in MFS 
and less effective in TAV and BAV patients.
Keywords Aorta · Aneurysm · Immunohistochemistry · 
Molecular biology · Pathology
Introduction
Bicuspid aortic valve (BAV) is the most common congeni-
tal cardiac malformation, with a prevalence of 1 % in the 
general population [1]. This anomaly is associated with 
complications as aortic stenosis and/or regurgitation as 
well as critical aortic dilation, with an increased risk of dis-
section and rupture. Aortic dilation is also a key feature of 
the clinical presentation in patients with Marfan syndrome 
(MFS). In MFS, mutations in the fibrillin-1 gene, encod-
ing for the fibrillin-1 protein, account for approximately 
70–93 % of patients who meet the diagnostic criteria [2]. 
Due to the fibrillin-1 mutation, the aorta in MFS exhibits 
Abstract Patients with bicuspid aortic valve (BAV) and 
patients with Marfan syndrome (MFS) are more prone to 
develop aortic dilation and dissection compared to persons 
with a tricuspid aortic valve (TAV). To elucidate potential 
common and distinct pathways of clinical relevance, we 
compared the histopathological substrates of aortopathy. 
Ascending aortic wall biopsies were divided in five groups: 
BAV (n = 36) and TAV (n = 23) without and with dilation 
and non-dilated MFS (n = 8). General histologic features, 
apoptosis, the expression of markers for vascular smooth 
muscle cell (VSMC) maturation, markers predictive for 
ascending aortic dilation in BAV, and expression of fibril-
lin-1 were investigated. Both MFS and BAV showed an 
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markedly abnormal elastic properties which are assumed to 
lead to a decrease in compliance and progressive increase 
in dilation [3].
Both patients with MFS and BAV show aortic dilation 
but the anatomic site of vulnerability is distinct in both con-
ditions. While maximal aortic dilation is observed above 
the sinotubular junction in BAV, in the MFS population, it 
is mainly found at the level of the sinuses of Valsalva, also 
referred to as aortic root [4].
To unravel the pathogenetic mechanism leading to aor-
tic wall pathology in BAV, differences between the dis-
eased aortic wall of patients with BAV and patients with a 
tricuspid aortic valve (TAV) were studied previously [5]. 
We found that the ascending aorta in BAV is intrinsically 
different from TAV patients. The vascular smooth muscle 
(VSMC) cell layer is less well differentiated in BAV, while 
inflammation and accelerated aging attribute to the aortic 
pathology in TAV [5].
Despite the VSMC immaturity, not all patients with BAV 
carry an increased risk for aortic dilation. In a previous 
study, we defined a panel of markers which could differ-
entiate the non-dilated BAV patients, in a susceptible and 
non-susceptible subgroup for future dilation, being c-Kit, a 
marker for dedifferentiated VSMCs, and its phosphorylated 
state (pc-Kit) triggered by the presence of matrix metallo-
proteinase-9 (MMP9) influencing hypoxia-inducible-fac-
tor-1-alpha (HIF1α) and endothelial nitric oxide synthase 
(eNOS) [6].
The aortic wall in MFS and BAV has been described 
to have similarities, like an increased MMP activity and 
decreased fibrillin-1 expression [7, 8]. However, cytolytic 
necrosis, (also termed medial degeneration), defined as 
VSMC dropout, apoptosis, and elastic fiber degeneration, 
highly characteristic for MFS and the dilated aorta in TAV, 
are far less obvious in BAV [5, 7]. Although clinically, 
symptoms of aortic wall pathology in MFS and BAV over-
lap, still some striking differences remain less well under-
stood. For instance, BAV patients rarely possess Marfanoid 
characteristics; conversely in patients with MFS, the risk 
of concomitant BAV syndrome is only slightly increased 
(4.7 %) [9]. Furthermore, the risk for aortic dilation in BAV, 
although higher than in the general population, remains low 
when compared to MFS where the majority of patients is 
prone to severe aortic wall disease. In MFS, moreover, not 
only aortic dilation is a critical aortic complication, but also 
dissections in a non-dilated aortic wall and at a younger 
age, as compared to the BAV, have been reported [10, 11]. 
In MFS furthermore, angiotensin-receptor-blockers (ARBs) 
as losartan have been identified as a potentially therapeu-
tic agent to prevent progressive dilation of the ascending 
aorta [12–18]. A similar positive effect in preventing aortic 
complications, by reducing the angiotensin pathway sign-
aling is, however, not seen in the BAV population [19]. It 
is therefore interesting to study which similarities are actu-
ally present immunohistochemically between the ascend-
ing aortic wall in both diseases and the dilated aortic wall 
in the TAV, despite possible different clinical sequelae in 
future. What factors cause increased weakness of the aortic 
wall in MFS and are these similar in BAV? Why is aortic 
wall pathology seen in BAV and MFS not comparable to 
the aortic dilation complications in patients with TAV?
To study this, we compared the aortic wall between 
MFS, BAV, and TAV, starting with the investigation of gen-
eral histopathological features, including cytolytic necro-
sis, inflammation, elastin lamellae degradation, and VSMC 
apoptosis. The level of expression of fibrillin-1 was also 
studied in these groups. As VSMCs play a role in the syn-
thesis and assembly of fibrillin-1, we compared our find-
ings of fibrillin-1 expression to that of differentiation and 
maturation of the vascular wall, being the VSMC differ-
entiation markers lamin A/C and progerin [5]. We further 
studied the expression of the pc-Kit pathway (c-Kit, pc-Kit, 
MMP9, HIF1α, and eNOS) to investigate whether these 
markers, indicative of BAV aortic dilation [6], are also 
applicable in the MFS group.
Materials and methods
Ethical statement
The institutional ethics committee at the Leiden University 
Medical Centre, Leiden approved this study. The Academic 
Medical Center (AMC), Amsterdam provided us with eight 
MFS biopsy aorta specimens, with approval of the Medical 
Ethical Committee. The Heart Valve Bank, Thoraxcenter, 
Erasmus Medical Center (EMC), Rotterdam, provided six 
non-dilated BAV aortic wall samples which were not suit-
able for transplantation, approved by their Scientific Advi-
sory Board.
Patients and tissue samples
Ascending aortic wall samples were collected from non-
MFS individuals with TAV and BAV, with and without 
dilation. Based on the ACC/AHA guidelines, dilation 
was clinically defined by surpassing an ascending aortic 
wall diameter of 45 mm [20]. The study population was 
divided in five groups: (1) TAV without dilation, termed TA 
(n = 11, mean age 64.5 ± 9.0 years) obtained post mor-
tem, (2) TAV with dilation, termed TAD (n = 12, mean age 
72.3 ± 11.2 years) collected during elective replacement, 
(3) BAV without dilation, termed BA (n = 17, mean age 
55.8 ± 9.8 years) representing a unique group from patients 
with stentless root replacement (the biopsy material was 
collected as residue waste material from the proximal 
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anastomosis), and the 6 biopsies received from the EMC, 
(4) BAV with dilation, termed BAD (n = 19, mean age 
60.7 ± 7.8 years), collected during elective replacement, 
and (5) MFS aortic wall without ascending aorta dila-
tion, termed MFS (n = 8, mean age 34.2 ± 11.0 years), 
derived after elective replacement of the dilated root (the 
biopsy material was collected as residue waste material 
from the proximal anastomosis). Groups one to four have 
been reported previously [5, 6], and in the current study, 
additional staining with fibrillin-1 and apoptosis markers 
was performed for comparison with the newly described 
MFS group. In this study, we paid additional attention to 
the underlying aortic valve pathology of the study popu-
lation. The TA group showed no valve pathology, and the 
TAD group showed variably either no valve pathology or 
aortic valve stenosis or regurgitation. In the non-dilated 
BAVs, six patients had a non-pathologic aortic valve; these 
were the specimens we received from the EMC, and the 
remainder of the BA group showed aortic valve stenosis, 
aortic valve regurgitation, or a combination of both. In the 
dilated BAV, group 3 patients had a non-pathologic aortic 
valve. All MFS patients had a non-pathologic valve and a 
dilated aortic root; specimens were hence obtained during 
a valve-sparing root replacement, which was performed in 
this patient group.
Sample processing and routine histology
Specimens were sectioned and stained as described previ-
ously [5, 6]. Briefly, following excision, all specimens were 
fixed, decalcified, and paraffin embedded. Transverse sec-
tions (5 µm) of the paraffin-embedded tissue were depar-
affinated and rehydrated after which they were stained with 
hematoxylin–eosin (HE) and resorcin fuchsin (RF) to study 
the morphology of the vessel wall. Aortic inflammation 
was quantified using the HE-stained sections, indexed from 
zero (no inflammatory cells) to 6 (large clusters of cells). 
In RF-stained sections, the maximum intimal thickness was 
quantified in µm and the organization of the elastic lamel-
lae in the media was evaluated.
Immunohistochemistry
Sections were stained following the protocol described pre-
viously [5, 6]. An overview of the primary and secondary 
antibodies used is given in Table 1.
Histologic parameters, immunohistochemical analyses, 
and morphometry
Sections were studied with a Leica BM500 microscope 
equipped with plan achromatic objectives (Leica Microsys-
tems, Wetzlar, Germany). Cytolytic necrosis and elastic 
fiber degeneration were defined qualitatively, in alpha-
smooth muscle actin (αSMA) and resorcin fuchsin (RF) 
stained sections, respectively. The cytoplasmatic level of 
expression of αSMA, smooth muscle-22-alpha (SM22al-
pha), smoothelin, and MMP-9, intra- and extracellular 
expression of fibrillin-1, cytoplasmatic and extracellu-
lar matrix expression of transforming growth factor-beta 
(TGFβ), and nuclear expression of lamin A/C, progerin, 
cleaved-caspase-3, eNOS, pc-Kit, and Hif1α were ana-
lyzed on three predetermined locations (left, middle, and 
right) of every section, that we refer to as ‘microscopic 
fields’ maintained in evaluation of all staining on sister sec-
tions. In each microscopic field, the level of expression was 
indexed on the three anatomical layers of the aortic wall 
(tunica intima, media, and adventitia) as 0 (no expression 
in the respective layer), 2 (expression in less than one third 
of the layer), 4 (expression in two thirds of the layer), and 
6 (expression in the whole layer). To determine the level of 
lamin A/C, progerin, cleaved-caspase-3, eNOS, pc-Kit and 
Hif1α expression, the number of positively stained nuclei 
was counted following previously described methods [6]. 
All specimens were re-evaluated by an independent, expe-
rienced histopathologist who was blinded to the clinical 
data.
Statistical analyses
All numerical data are presented as mean ± SD of three 
microscopic fields on each stained slide. Statistical differ-
ences were evaluated with the Mann–Whitney U test for 
comparison between the groups. We also performed a one-, 
two-, and three-way ANCOVA test to correct for age and 
gender. Significance was assumed when p < 0.05 using 
SPSS 20.0 software program (SPSS Inc., Chicago, USA). 
Graphpad software was used to create graphics of statisti-
cal analysis.
Results
Patient characteristics
Patient characteristics of all five groups are shown in 
Table 2. The MFS patients were evidently the youngest, 
followed by the BAV patients. In MFS, male and female 
were almost equally affected; the BAVs, however, showed 
a marked male predominance. There was thus a noticeable 
variance in age and gender distribution in our study. Statis-
tically, both age and gender were not found confounding in 
our study.
All MFS patients showed typical aortic root dilation 
(diameter 48.1 ± 3.0 mm), with a non-dilated ascending 
aorta (diameter 28.4 ± 12.8 mm). Marked root dilation was 
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not present in the other four groups (TA, BA, TAD, and 
BAD).
General histopathologic features in aortic walls of MFS, 
BAV, and TAV
The ascending aortic wall, consisting of a tunica intima, 
media, and adventitia, was compared between the MFS, 
BAV (BA, BAD), and TAV (TA, TAD) groups. The total 
vessel wall thickness, excluding the highly variable adven-
titia, was not different between the 5 groups.
Intima Similar to BAV [5], in MFS, the intima was sig-
nificantly thinner as compared to the TAV groups (MFS vs 
TAD p < 0.001) (Fig. 1a, b, f). Previously we described that 
in all specimens from BAV patients, the intima also showed 
a significantly lower intimal expression of TGFβ as com-
pared to TAV [6]. When analyzed in the MFS group, we 
found that in this group, the intima also had a very low 
TGFβ expression (Fig. 1c).
Media Of all groups, only the aortic wall of MFS and 
TAD showed significant pathology in the media, with 
more profound cytolytic necrosis (Fig. 1d) and a more 
fragmented pattern of the elastic lamellae in which the 
inter-lamellar distance was enlarged (Fig. 1e). These signs 
of pathology were not observed in the TA, BA, and BAD 
groups (not shown). Expression of the apoptosis marker 
cleaved-caspase-3 was markedly elevated in the media of 
MFS and TAD as compared to the BAD (p = 0.033 and 
p = 0.0286, respectively) (Fig. 1h).
Adventitia The adventitia consisted of loose fibrous tis-
sue containing nerve fibers, fibroblasts, adipocytes, and 
vasa vasorum, lined by endothelium and VSMCs in all 
groups. Adventitial inflammatory cells were most outspo-
ken in the TAD group as compared to the MFS and BAD 
group (p < 0.0001, p < 0.001, respectively) (Fig. 1a, g).
In conclusion, intimal thickness and lack of adventitial 
inflammation were similar between BAV and MFS. Aortic 
media pathology was comparable between the non-dilated 
MFS and dilated TAV.
Fibrillin‑1, differentiating and mature VSMCs, lamin 
A/C, progerin, and the pc‑Kit pathway
To further understand the pathobiology, we focused on the 
differentiation state of the aortic wall and the expression of 
the pc-Kit pathway and fibrillin-1 in all patient groups.
Fibrillin-1 expression was identified in the aortic media 
of all groups. The total number of cells (positively and neg-
atively stained nuclei) was not different between all inves-
tigated specimens from the various groups. The level of 
expression was, however, significantly lower in all patients 
with MFS and BAV (BA, BAD) as compared to TAV (TA, 
TAD) (p < 0.05) (Fig. 2a–f). The localization of the stain-
ing was different between the groups. In the TAV (TA and 
TAD), the staining was mainly seen extracellular, whereas 
in the MFS and BAV besides being decreased, the expres-
sion was mainly observed intracellular (cytoplasmic) in the 
VSMCs (Fig. 2a–e).
We further observed that in MFS, the expression of the 
differentiated smooth muscle cell markers αSMA (Fig. 3e), 
SM22α (Fig. 3a, f), and smoothelin (Fig. 3b) was similar to 
the BAVs and significantly lower as compared to the TAVs 
group. The decreased expression of these markers suggests 
an immature smooth muscle cell phenotype and less con-
tractility of the vessel wall [21–23]. Expression of lamin 
A/C (Fig. 3c, g) and progerin (Fig. 3d, h) in MFS was as 
seen in BAV, being lower as compared to the TAVs. Thus, 
the aortic wall in MFS shows features of less differentiation 
comparable with the BAV group. The results are summa-
rized in Table 3.
Table 2  Clinical characteristics of all patients
a Data unavailable, clinically defined as non-dilated by pathologist
b Data unavailable for 5 patients, clinically defined as non-dilated by pathologist
c Aortic root diameters unavailable
Characteristics TA (N = 11) TAD (N = 12) BA (N = 17) BAD (N = 19) MFS (N = 8)
Age (years) 64.5 ± 9.0 72.3 ± 11.2 55.8 ± 9.8 60.7 ± 7.8 34.1 ± 11.8
Males (%) 54.5 33.3 70.1 84.2 62.5
Females (%) 45.5 66.7 29.4 15.8 37.5
Ascending aorta diameter (mean) a 55.0 ± 10.7 36.5 ± 7.4b 52.7 ± 6.2 28.4 ± 12.8
Aortic root diameter (mean) c c c c 48.1 ± 3.0
Aortic valve pathology
 No valve pathology N = 11 N = 6 N = 6 N = 3 N = 7
 Aortic stenosis N = 0 N = 1 N = 4 N = 8 N = 0
 Aortic regurgitation N = 0 N = 5 N = 1 N = 5 N = 1
 Aortic stenosis and regurgitation N = 0 N = 0 N = 5 N = 3 N = 0
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We further investigated markers predictive for ascending 
aortic dilation in BAV, including pc-Kit [6]. We found that 
these markers were not expressed in the MFS group (data 
not shown).
Discussion
Our study describes an in-depth effort to compare the 
ascending aortic wall of patients with MFS (non-dilated), 
BAV (non- and dilated), and TAV (non- and dilated) in one 
study. A specific aortic wall architecture associated with 
aortic wall pathology in both MFS and BAV is an exten-
sively discussed, yet controversial, subject. Previous studies 
compared the aortic wall of MFS and BAV histologically 
and found that the media were characterized by cytolytic 
necrosis and elastic fiber degeneration in both diseases 
[24]. An increased MMP activity and decreased fibrillin-1 
in the aortic wall, without comparable reduction in matrix 
components elastin and collagen, were further noticed [4, 
Fig. 1  General histologic 
features in Marfan syndrome. 
Transverse histologic sections 
(5 µm) stained with resorcin 
fuchsin (RF), hematoxylin–
eosin (HE) and alpha-smooth 
muscle actin (αSMA) in Marfan 
syndrome (MFS). HE-stained 
overview section (a) shows the 
tunica intima (i), which was 
significantly thinner (b, f) and 
lacked TGF-β expression in all 
MFS (c) and BAV patients as 
compared to the TAV groups, 
tunica media (m) and tunica 
adventitia (a). The aortic media 
of MFS and TAD showed sig-
nificant pathology in the media, 
with more profound cytolytic 
necrosis (CN) (d) and a more 
fragmented pattern of the elastic 
lamellae in which the inter-
lamellar distance (arrow) was 
enlarged (e). Adventitial inflam-
matory cells were absent in the 
MFS (a) and most outspoken in 
the TAD group (g). Expression 
of the apoptosis marker cleaved-
caspase-3 was significantly 
elevated in the media of MFS 
and TAD as compared to the 
BAD (h). Magnification a 
×4, b–e ×40. ***p < 0.001, 
****p < 0.0001
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7, 8]. Similarities have thus been noted, though without 
getting grip on a possible common defect. In this study, 
we attempted to shed light on intrinsic defects of the aortic 
wall leading to the observed similarities by comparing the 
ascending aortic wall of both diseases with each other and 
with patients with TAV without MFS. As recently several 
publications focused on a difference in dilation progress 
after aortic valve repair dependent on whether the diseased 
aortic valve was stenotic or regurgitant with concomitant 
root dilation [25, 26]; in the latter, we also paid additional 
attention to the underlying aortic valve pathology besides 
structural histopathologic features in the patient groups. 
In the literature, it is argued that the aortic dilation in the 
stenotic type is a functional hemodynamic-induced prob-
lem, while the aortic wall problem in the root phenotype is 
genetically determined. Therefore, an isolated aortic valve 
Fig. 2  Fibrillin-1 level of 
expression. Transverse histo-
logic sections (5 µm) stained 
with fibrillin-1. TA (tricus-
pidy without dilation), TAD 
(tricuspidy with dilation), BA 
(bicuspidy without dilation), 
BAD (bicuspidy with dilation), 
MFS (Marfan syndrome without 
dilation). FBN-1 expression was 
observed in the aortic media (m) 
of all groups, with each picture 
(a–e) showing an inset with 
magnification ×100 to illustrate 
the expression on cellular 
level. The level of expression 
was significantly lower in all 
patients with MFS (e), BA (c), 
and BAD (d) as compared to 
TA (a) and TAD (b, f). Staining 
was mainly extracellular in the 
TA and TAD, whereas in the 
MFS and BAV, the decreased 
expression was mainly observed 
intracellular (cytoplasmic) in 
the VSMC. Magnification a–e 
×40. *p < 0.05, **p < 0.01
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replacement in stenotic BAV patients is believed to halt the 
aortic wall dilation. Girdauskas et al. further state that BAV 
patients with root dilation require a more aggressive surgi-
cal approach, being a genetic, connective tissue disorder-
like form of aortic disease which is independent of trans-
valvular flow perturbations [25]. We, however, do not agree 
on this differentiation into two main groups for a several 
reasons. Firstly, we postulate that all BAVs are intrinsically 
a congenital malformation (Grewal et al.) and that an early 
developmental concomitant defect during embryogenesis 
contributes to the abnormal maturation of the vascular wall 
of the ascending aorta independent of a subsequent stenotic 
Fig. 3  Differentiation markers 
in Marfan syndrome. Trans-
verse histologic sections (5 µm) 
stained with smooth muscle 
22 alpha (SM22α), smoothe-
lin, lamin A/C, and progerin, 
markers for differentiation 
state of VSMCs. SM22α (a, f), 
αSMA (e), and smoothelin (b) 
expression in MFS was similar 
to BAD and significantly lower 
as compared to TAD. Expres-
sion of lamin A/C (c, g) and 
progerin (d, h) in MFS was 
also significantly lower than in 
TAD. Magnification a–d ×100. 
*p < 0.05, **p < 0.01
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or a root phenotype [27]. Secondly, as shown in Table 2, 
in our study population, aortic valve pathology in non- and 
dilated BAV and dilated TAV was highly variable showing 
either stenosis or no stenosis, with or without regurgita-
tion. The dilated BAV and MFS groups even consisted of 
patients without valve pathology, which indicates that even 
in the absence of specific aortic valve pathology, aortic 
complications can occur. We can however not completely 
refute the influence of hemodynamics on the development 
of aortic wall complications, as we do not have follow-up 
data of the operated patients. This is a limitation of our 
study and an important aspect which should be taken into 
account in future research.
Histopathologically, in our study, patients in the BAV 
group did not show marked degenerative features in the 
aortic media [5], which has also been reported earlier [28, 
29]. The media of the ascending aorta in MFS, however, 
showed resemblance with the TAD with significant cyto-
lytic necrosis, VSMC apoptosis, and degradation of the 
elastic lamellae, which could predispose the aortic wall 
for dissection. The MFS group thus showed characteris-
tics of a weak aortic wall, although strikingly the patho-
logic aorta was not even markedly dilated in the MFS study 
population as compared to the TAD (Table 2). A role for 
increased MMP9 production in the occurrence of cytolytic 
necrosis and extracellular matrix production responsible 
for increased inter-elastic lamellar distance in TAD and 
MFS was not supported by our studies. The only marked 
increase of MMP9 was observed in the non-dilated, sus-
ceptible BAV with no marked cytolytic necrosis. So further 
studies are needed into the role for MMP9 in aortic wall 
pathology.
To further elucidate the high incidence of aortic wall 
pathology in MFS and BAV, we studied the level of fibril-
lin-1 expression. The immature aortic wall of BAV and 
MFS shared a marked resemblance in the level of expres-
sion of fibrillin-1. Decreased fibrillin-1 mRNA and 
fibrillin-1 protein have been demonstrated before in BAV 
individuals [8] and can lead to dissociation of VSMCs from 
medial matrix components [30]. The diagnosis of MFS is 
however clinical and relies on a set of defined clinical cri-
teria (the Ghent nosology) [2]. The new diagnostic criteria 
emphasize cardiovascular manifestations of the disorder, 
in which aortic root aneurysm is one of the prime features. 
Recently, Pepe et al. [31] identified two fibrillin-1 muta-
tions in a population of eight BAV patients. These muta-
tions had never been detected in MFS patients before. 
Moreover, these BAV patients did not meet the clinical 
MFS criteria; therefore, they were not diagnosed with MFS 
[31]. We can conclude that in the present study and previ-
ous studies, a decrease in fibrillin-1 has been reported in 
four conditions: patients with BAV without a fibrillin-1 
mutation [8] (current study), patients with BAV and a fibril-
lin-1 mutation with [9] or without [31] clinical MFS fea-
tures, and finally patients with clinically MFS and a fibril-
lin-1 mutation but no BAV [32].
As fibrillin-1 is produced by VSMCs [33], a significant 
decrease (of structurally normal) fibrillin-1 is plausible in 
an aortic wall which constitutes less well-differentiated 
VSMCs, also without apparent fibrillin-1 mutations. As 
described in this study, in both MFS and BAV, the aortic 
wall is primarily less well differentiated which can explain 
the secondary decrease in the (structurally normal) expres-
sion of fibrillin-1. Besides a decreased amount of fibrillin-1 
in the aortic wall, in line with earlier research, we found 
that the distribution and localization of fibrillin-1 was dif-
ferent in the MFS and BAV, with more accumulation within 
the VSMCs [7, 34, 35], whereas it was mostly seen extra-
cellular in the TAVs. As earlier described by Nataatmadja 
et al., the few extracellular fibers observed in BAV and 
MFS were thick and short [7]. Hollister et al. also found a 
deficiency in the amount of microfibrillar fibers, analyzed 
immunohistochemically [35], comparable with our results.
As described above, cytolytic necrosis and VSMC apop-
tosis are observed in both MFS and TAV. However, VSMC 
apoptosis, which leads to cytolytic necrosis, seems to occur 
due to a different pathogenetic mechanism in MFS as com-
pared to TAV. In TAV, aging, accompanied by an increased 
progerin expression, and atherosclerosis cause VSMC 
apoptosis [5, 36], whereas as we have seen in this study in 
MFS these features are not apparent. In MFS, the media 
of the aortic wall contain less well-differentiated VSMCs 
similar to BAV. Therefore, we hypothesize that there must 
be a different pathway leading to cytolytic necrosis in 
MFS, which is on the one hand not related to cardiovas-
cular aging, but on the other hand can also not be associ-
ated directly to the immature state of the VSMCs as in BAV 
where cytolytic necrosis scarce [5, 28].
VSMC apoptosis and subsequent cytolytic necrosis 
in MFS have earlier been described to occur at a much 
Table 3  Summary of the results
TA TAD MFS BA BAD
Intimal thickness +++ +++ ± ± ±
TGFβ intima expression ++ ++ − − −
Inflammation ± +++ ± ± ±
Cytolytic necrosis − + + − −
Apoptosis ++ +++ ++ + +
Elastic lamellae degeneration − + + − −
Fibrillin-1 +++ +++ + + +
VSMC expression (αSMA,  
SM22α, smoothelin)
+++ +++ ± ± ±
Lamin A/C +++ +++ + + +
Progerin + +++ + + +
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younger age as compared to the TAV and as a direct con-
sequence of the fibrillin-1 mutation which leads to an 
increased Angiotensin II (AT2) receptors signaling and 
subsequently induction of TGFβ signaling [37–39]. We 
postulate that two different pathologic pathways might thus 
be distinguished leading to aortic dissections. For clarifica-
tion, we have schematically provided a working hypothesis 
(Fig. 4) showing how the various differentiation pathways 
and the involved gene pathways could lead to the observed 
histopathological similarities and differences we have seen 
between the investigated groups. In MFS, there is thus a 
combination of immaturity of the aortic media and cytol-
ytic necrosis, due to increased VSMC apoptosis, related to 
increased AT2 receptor signaling [31, 32], rendering the 
aortic wall very weak. These observations could explain 
why angiotensin-receptor-blockers (ARBs), as losartan, 
have been identified as a potentially therapeutic agent 
to prevent progressive dilation of the ascending aorta in 
MFS. ARBs reduce the signaling that occurs through both 
AT receptors, (AT1 and AT2 receptor). Many trials have 
emerged in recent years investigating the efficacy of ARB’s 
in human patients with MFS [12–18]. The first results from 
these studies show reduced dilation of the aortic root in 
MFS with losartan [17].
A similar positive effect has not been reported in a pop-
ulation of BAV patients who were treated with an angio-
tensin inhibitor (ACE inhibitor) [19] which can be under-
stood on the basis of our current results. In BAV, medical 
treatment is not effective because the aortic wall in BAVs 
is not characterized by apoptosis and cytolytic necro-
sis. In conclusion, comparison of the aortic wall samples 
in BAV, MFS, and TAV seems to demonstrate that aortic 
dissections in MFS might have a different pathogenesis as 
compared to the TAV, explaining the higher incidence and 
the younger age of occurrence. These findings could be rel-
evant for understanding why medical treatment to inhibit 
Fig. 4  Working hypothesis. Schematic overview of our working 
hypothesis regarding similarities and differences in aortic wall pathol-
ogy between bicuspid aortic valve (BAV), tricuspid aortic valve 
(TAV), and Marfan syndrome (MFS). According to our hypothesis, 
the ascending aortic wall can be classified as being either mature or 
less well differentiated. Patients with a TAV have a differentiated/
mature vascular wall [differentiated vascular smooth muscle cells 
(VSMCs) and lamin A/C] in which cardiovascular aging (increased 
expression of progerin with increased apoptosis, atherosclerosis, and 
inflammation) accompanies degeneration with features of cytolytic 
necrosis (CN). This progressive aortic wall pathology in TAV thus 
leads to a weakened aortic media causing complications as aortic 
dilation and dissection. In BAV and MFS, weakness of the aorta is 
however caused by immaturity of the aortic wall (deficient differen-
tiated VSMCs and lamin A/C expression) instead of aging. Fibril-
lin-1, pivotal for structural stability of the vessel wall, is produced 
by VSMCs. Immaturity of the vessel thus leads to a quantitative 
decrease of fibrillin-1 in both BAV and MFS. In MFS, additionally, 
the FBN1 (fibrillin-1) mutation leads to VSMC apoptosis through an 
increased signaling of angiotensin II receptors (AT2 receptor). CN, 
caused by VSMC apoptosis, in combination with the immature state 
of the aortic media renders the vascular wall extremely weak, most 
probably presenting a different pathogenesis of aortic dissection in 
MFS as compared to the TAV
805Heart Vessels (2016) 31:795–806 
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angiotensin is seemingly successful in MFS and less effec-
tive in TAV and BAV patients also being prone for aortic 
wall pathology.
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